20:23 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Merz’s Xeomin meets in Phase III trial for PD-associated sialorrhea

The Merz Neurosciences unit of Merz GmbH & Co. KGaA (Frankfurt, Germany) reported top-line data from the Phase III SIAXI trial to treat sialorrhea associated with Parkinson’s disease (PD) and other neurological disorders showing that...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Xeomin incobotulinumtoxinA regulatory update

FDA approved an sBLA from Merz for Xeomin incobotulinumtoxinA to treat upper limb spasticity in adults. Xeomin is marketed in the U.S. to treat cervical dystonia, blepharospasm and glabellar lines. The product is botulinum neurotoxin...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Merz sales and marketing update

Merz's U.S. subsidiary Merz Pharmaceuticals LLC will launch on April 1 the My Merz Select physician loyalty program for its aesthetic products. Merz markets OTC aesthetic products and prescription aesthetic products, including Xeomin incobotulinumtoxinA. The...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Allergan, Merz neurology news

The U.S. District Court for the Central District of California granted a motion from Merz to modify a permanent injunction and terminate portions that prevented Merz from selling Xeomin incobotulinumtoxinA. In March, the court entered...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

Xeomin Cosmetic regulatory update

Merz said Health Canada approved Xeomin Cosmetic incobotulinumtoxinA as a temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows) in adult patients. The company said the product will...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Allergan, Merz neurology news

Allergan said a federal judge in the U.S. District Court for the Central District of California issued an injunction preventing Merz from selling Xeomin incobotulinumtoxinA in facial aesthetics indications to certain physicians in the U.S....
08:00 , Jan 9, 2012 |  BC Week In Review  |  Clinical News

Xeomin incobotulinumtoxinA regulatory update

Merz said the Centers for Medicare & Medicaid Services (CMS) issued a permanent J-code for reimbursement of Xeomin incobotulinumtoxinA. J0588, the code for Xeomin, became effective on Jan. 1. The botulinum neurotoxin type A is...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

Merz sales and marketing update

Merz launched Xeomin incobotulinumtoxinA in the U.S. as a temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows). Merz already markets Xeomin in the U.S. to treat cervical...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

Xeomin incobotulinumtoxinA regulatory update

The Scottish Medicines Consortium recommended the use of Merz's Xeomin incobotulinumtoxinA on the National Health Service (NHS) in Scotland to treat post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

Xeomin regulatory update

FDA approved Xeomin incobotulinumtoxinA from Merz as a temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows). Merz, which expects to launch the product in spring 2012 for...